15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ipilimumab is an anti-CTLA-4 antibody which has recently been approved in Europe as a monotherapy in the treatment of metastatic melanoma. We report a single-center study among patients treated within a Temporary Authorization for Use (TAU) protocol. We also performed a review of the literature involving expanded access program studies with a focus on factors associated with overall survival (OS).

          Related collections

          Author and article information

          Journal
          Eur J Dermatol
          European journal of dermatology : EJD
          1952-4013
          1167-1122
          : 25
          : 1
          Affiliations
          [1 ] APHP Department of Dermatology Hôpital Saint-Louis, 1, avenue Claude-Vellefaux. 75010 Paris, France; Université Paris 7-Diderot, INSERM U976.
          [2 ] APHP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University.
          [3 ] APHP Department of Pharmacy Hôpital Saint-Louis ; Université Paris 7-Diderot, Paris, France.
          Article
          ejd.2014.2471
          10.1684/ejd.2014.2471
          25500362
          8ab669f8-07ad-49af-9fd8-a9d94be58fdb
          History

          baseline corticosteroids,ipilimumab,melanoma
          baseline corticosteroids, ipilimumab, melanoma

          Comments

          Comment on this article